5,577 Shares in TransMedics Group, Inc. $TMDX Acquired by Intrust Bank NA

Intrust Bank NA acquired a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 5,577 shares of the company’s stock, valued at approximately $747,000.

A number of other large investors have also recently modified their holdings of the business. CWM LLC raised its holdings in shares of TransMedics Group by 20.1% during the 1st quarter. CWM LLC now owns 925 shares of the company’s stock worth $62,000 after buying an additional 155 shares in the last quarter. Victory Capital Management Inc. raised its stake in TransMedics Group by 3.8% during the first quarter. Victory Capital Management Inc. now owns 8,365 shares of the company’s stock worth $563,000 after acquiring an additional 308 shares in the last quarter. Jennison Associates LLC lifted its holdings in shares of TransMedics Group by 3.6% in the first quarter. Jennison Associates LLC now owns 9,217 shares of the company’s stock worth $620,000 after acquiring an additional 316 shares during the last quarter. Lindbrook Capital LLC boosted its stake in shares of TransMedics Group by 69.3% in the 1st quarter. Lindbrook Capital LLC now owns 2,742 shares of the company’s stock valued at $184,000 after purchasing an additional 1,122 shares in the last quarter. Finally, Allianz Asset Management GmbH bought a new stake in shares of TransMedics Group during the 1st quarter valued at approximately $343,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

TMDX has been the subject of several research reports. Needham & Company LLC reissued a “buy” rating on shares of TransMedics Group in a research note on Thursday, October 30th. Piper Sandler lowered their price target on shares of TransMedics Group from $145.00 to $140.00 and set an “overweight” rating for the company in a report on Thursday, October 30th. Jefferies Financial Group assumed coverage on TransMedics Group in a report on Monday, October 13th. They set a “buy” rating and a $145.00 price objective on the stock. Stifel Nicolaus assumed coverage on TransMedics Group in a research report on Thursday, September 4th. They set a “hold” rating and a $115.00 price objective on the stock. Finally, Evercore ISI assumed coverage on TransMedics Group in a research report on Tuesday, September 16th. They issued an “outperform” rating and a $155.00 target price for the company. Seven analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $131.80.

Insider Activity at TransMedics Group

In related news, Director Edward M. Basile sold 4,142 shares of the company’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $130.45, for a total value of $540,323.90. Following the sale, the director directly owned 2,866 shares in the company, valued at $373,869.70. This represents a 59.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 7.00% of the stock is currently owned by corporate insiders.

TransMedics Group Stock Performance

Shares of TransMedics Group stock opened at $113.40 on Tuesday. The stock has a market cap of $3.87 billion, a price-to-earnings ratio of 45.91 and a beta of 2.05. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $145.50. The company’s fifty day moving average is $118.98 and its 200 day moving average is $120.14. The company has a quick ratio of 7.13, a current ratio of 7.69 and a debt-to-equity ratio of 1.43.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Wednesday, October 29th. The company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.37 by $0.29. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.The firm had revenue of $143.82 million for the quarter, compared to the consensus estimate of $145.33 million. During the same period in the previous year, the business earned $0.12 EPS. The business’s quarterly revenue was up 32.2% compared to the same quarter last year. TransMedics Group has set its FY 2025 guidance at EPS. Sell-side analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.